Welcome to episode 71 of The 5-Minute Investor Podcast, where Stockhouse columnists Jonathon Brown and me, Trevor Abes, each deliver a 2.5-minute profile on a stock related to recent investment news. This week, with about 40 per cent of US citizens qualifying as obese, about 30 per cent in Canada, and more than 1 billion people affected across the world, weight-loss drugs have stepped into the pharmaceutical landscape as a convenient solution to this debilitating disease, presenting investors with numerous stocks worth considering for a potential investment.
This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
Here are Jon’s show notes for episode 71:
- Jon’s weight-loss drug stock in focus is Structure Therapeutics (NASDAQ:GPCR), a clinical-stage biopharmaceutical company focused on oral small molecule treatments for chronic metabolic conditions.
- A small-cap contender looking to challenge the weight-loss drug giants.
- At the time of writing, Structure Therapeutics stock last traded at US$49.12, adding 173.80 per cent year-over-year and 88.92 per cent since inception in 2023.
Here are Trevor’s show notes:
- Trevor’s weight-loss drug stock with tangible potential is Viking Therapeutics (NASDAQ:VKTX), a company vying to develop the first dual GLP-1 and GIP receptor agonist available in both oral and injectable formulations.
- Viking Therapeutics announces completion of enrollment in phase 3 VANQUISH-1 trial of VK2735.
- Viking Therapeutics reports first quarter 2026 financial results.
- At the time of writing, Viking Therapeutics stock last traded at US$34.79, adding 1.07 per cent year-over-year and 502.95 per cent since 2021.
Here’s our most recent trio of episodes:
- Episode 68: First-class airline stocks.
- Episode 69: Gaming’s new dark reality.
- Episode 70: Wildfires, AI and opportunity.
Thanks for listening!
The 5-Minute Investor Podcast is on Spotify, YouTube, iHeartRadio, Stockhouse or wherever finer podcasts are found.
Join the discussion: Find out what investors are saying about these weight-loss drug stocks on the Structure Therapeutics Inc. and Viking Therapeutics Inc. Bullboards and make sure to explore the rest of Stockhouse’s stock forums and message boards.